Bayer CropScience (506285) Aandelenoverzicht
Bayer CropScience Limited houdt zich bezig met de productie, verkoop en distributie van insecticiden, fungiciden, herbiciden en verschillende andere agrochemische producten en maïszaden in India, Duitsland, Bangladesh en internationaal. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 1/6 |
| Toekomstige groei | 2/6 |
| Prestaties in het verleden | 6/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 4/6 |
506285 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Bayer CropScience Limited Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | ₹4,131.75 |
| 52 Week Hoogtepunt | ₹6,539.95 |
| 52 Week Laag | ₹4,030.00 |
| Bèta | 0.23 |
| 1 maand verandering | -3.93% |
| 3 maanden verandering | -13.83% |
| 1 Jaar Verandering | -33.19% |
| 3 jaar verandering | -10.03% |
| 5 jaar verandering | -30.60% |
| Verandering sinds IPO | 5,409.00% |
Recent nieuws en updates
506285: Dividend Strength And Compostable Nursery Initiative Will Support Upside Potential
The analyst price target for Bayer CropScience has been modestly adjusted to ₹5,186.83 from ₹5,163. This reflects updated views on a slightly higher profit margin outlook, a revised discount rate and a recalibrated future P/E assumption.506285: Dividend Outlook And Updated Assumptions Will Support A Positive Future
Analysts have adjusted their price target for Bayer CropScience slightly lower from ₹5,209.63 to ₹5,163.00, citing updated assumptions around the discount rate, revenue growth, profit margin and future P/E. What's in the News Bayer CropScience has scheduled a Board Meeting for May 26, 2026, to consider and record the audited financial results for the quarter and financial year ended March 31, 2026, and to consider a recommendation for a final dividend for the 2025-26 financial year, if any.Recent updates
506285: Dividend Strength And Compostable Nursery Initiative Will Support Upside Potential
The analyst price target for Bayer CropScience has been modestly adjusted to ₹5,186.83 from ₹5,163. This reflects updated views on a slightly higher profit margin outlook, a revised discount rate and a recalibrated future P/E assumption.506285: Dividend Outlook And Updated Assumptions Will Support A Positive Future
Analysts have adjusted their price target for Bayer CropScience slightly lower from ₹5,209.63 to ₹5,163.00, citing updated assumptions around the discount rate, revenue growth, profit margin and future P/E. What's in the News Bayer CropScience has scheduled a Board Meeting for May 26, 2026, to consider and record the audited financial results for the quarter and financial year ended March 31, 2026, and to consider a recommendation for a final dividend for the 2025-26 financial year, if any.506285: Stable Assumptions And Upcoming Results Will Shape A Balanced Outlook
Analysts have maintained their fair value estimate for Bayer CropScience at ₹5,209.63 per share, making only minor adjustments to assumptions such as discount rate, revenue growth, profit margin and future P/E. This suggests that their overall view on the stock's long-term potential remains broadly unchanged.506285: Upcoming Results And Refined Assumptions Will Support A Balanced Outlook
The analyst price target for Bayer CropScience has been adjusted slightly higher to ₹5,209.63 from ₹5,187.13. Analysts point to updated fair value estimates, a modest change in the assumed discount rate, and revised expectations for revenue, profit margins, and future P/E as key inputs behind this move.506285: Upcoming Results And Stable Assumptions Will Support A Balanced Outlook
Analysts have kept their price target on Bayer CropScience broadly unchanged around ₹5,187. This reflects only marginal model tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, rather than any shift in their core view.506285: Upcoming Results And Stable Assumptions Will Support A Positive Outlook
Analysts have marginally revised their price target for Bayer CropScience to ₹5,187, reflecting small tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E, rather than any major shift in the outlook. What's in the News A board meeting is scheduled for February 11, 2026, to review and consider the unaudited financial results for the quarter ended December 31, 2025 (Key Developments).506285: Sustainability Partnership And Upcoming Results Will Support A Positive Outlook
Analysts have kept their price target for Bayer CropScience broadly unchanged around ₹5,187, citing only small tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E that do not materially alter their overall view on the stock. What's in the News Bayer CropScience has scheduled a board meeting on February 11, 2026 to consider the unaudited financial results for the quarter ended December 31, 2025 (company filing).506285: Sustainability Collaboration And Upcoming Results Will Support A Balanced Outlook
Analysts have trimmed their price target for Bayer CropScience to ₹5,187 from about ₹5,278, reflecting updated views on slightly lower fair value, a modestly adjusted discount rate, marginally different margin expectations and a revised future P/E assumption, while keeping revenue growth assumptions largely supportive. What's in the News Bayer CropScience has scheduled a board meeting on February 11, 2026 to consider the unaudited financial results for the quarter ended December 31, 2025 (company filing).506285: Expanded Sustainability Partnership Will Support Bullish Outlook Into Next Year
Analysts have kept their fair value estimate for Bayer CropScience effectively unchanged at €5,277.67, with only marginal tweaks to assumptions such as discount rate, revenue growth, profit margin and future P/E. This reflects steady underlying expectations rather than a shift in view.506285: Farmer Focused Sustainability Partnership Will Support Bullish Outlook Into Next Year
Analysts have slightly reduced their fair value estimate for Bayer CropScience to about €5,278. This reflects modest tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E, without a major shift in the overall thesis.506285: Interim Dividend Decision Will Support Bullish Outlook Into Next Year
Analysts have kept their fair value estimate for Bayer CropScience steady, with only marginal tweaks to the discount rate, revenue growth, profit margin, and future P/E assumptions guiding a largely unchanged price target narrative. What's in the News A board meeting is scheduled for November 7, 2025, to review the unaudited financial results for the quarter ended September 30, 2025.506285: Interim Dividend Decision Will Drive Bullish Momentum Into Next Year
Analysts have modestly raised their price target on Bayer CropScience by about €5, citing a slightly higher long term discount rate and valuation assumptions that leave fair value largely unchanged. What's in the News Board meeting scheduled for November 7, 2025, to review unaudited financial results for the quarter ended September 30, 2025 (Key Developments) Board to consider declaration of an interim dividend for the financial year 2025 to 2026 at the November 7, 2025 meeting (Key Developments) Record date for the proposed interim dividend to be fixed during the upcoming board meeting (Key Developments) Valuation Changes The discount rate has risen slightly from 13.34% to 13.35%, reflecting a marginally higher required return on equity.506285: Interim Dividend Decision Will Drive Bullish Sentiment Into 2025
Narrative Update on Bayer CropScience Analysts have trimmed their price target for Bayer CropScience by approximately EUR 275, reflecting slightly softer expectations for revenue growth and profit margins, even as long term valuation multiples remain supportive. What's in the News A board meeting is scheduled for November 7, 2025 to review the unaudited financial results for the quarter ended September 30, 2025.506285: Interim Dividend Consideration Will Drive Bullish Momentum Into 2025
Narrative Update on Bayer CropScience Analysts have lowered their fair value estimate for Bayer CropScience from €5,939 to €5,556. They attribute this reduction to a slightly lower projected profit margin, which outweighs improvements in expected revenue growth and a modest decrease in the discount rate.Seeds, Traits And Biofuels Will Unlock New Value Pools
Strategic cost reductions and efficiency improvements are expected to enhance net margins and unlock substantial additional cash.Rendement voor aandeelhouders
| 506285 | IN Chemicals | IN Markt | |
|---|---|---|---|
| 7D | -0.2% | -1.9% | -0.9% |
| 1Y | -33.2% | -6.0% | -2.1% |
Rendement versus industrie: 506285 presteerde slechter dan de Indian Chemicals -sector, die het afgelopen jaar een rendement van -6 % opleverde.
Rendement versus markt: 506285 presteerde slechter dan Indian Market, dat het afgelopen jaar een rendement van -2.1 % opleverde.
Prijsvolatiliteit
| 506285 volatility | |
|---|---|
| 506285 Average Weekly Movement | 2.9% |
| Chemicals Industry Average Movement | 6.2% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.2% |
| 10% least volatile stocks in IN Market | 3.9% |
Stabiele aandelenkoers: 506285 heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de Indian markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 3% ) van 506285 is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1896 | 1,169 | Simon-Thorsten Wiebusch | www.bayer.in |
Bayer CropScience Limited houdt zich bezig met de productie, verkoop en distributie van insecticiden, fungiciden, herbiciden en verschillende andere agrochemische producten en maïszaden in India, Duitsland, Bangladesh en internationaal. Het bedrijf levert medicijnen voor de therapeutische gebieden cardiologie, gynaecologie, diabetes, oncologie en oogheelkunde, en apparatuur voor computertomografie, röntgen en magnetische resonantie. Daarnaast biedt het bedrijf gezondheidsproducten voor de consument die worden gebruikt als dagelijkse gezondheidsoplossing voor de behandeling van kleine ziekten, en verkoopt en distribueert het hybride zaden, zoals maïs en padie.
Bayer CropScience Limited Samenvatting
| 506285 fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | ₹185.15b |
| Inkomsten(TTM) | ₹6.89b |
| Inkomsten(TTM) | ₹56.75b |
Is 506285 overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| 506285 resultatenrekening (TTM) | |
|---|---|
| Inkomsten | ₹56.75b |
| Kosten van inkomsten | ₹33.78b |
| Brutowinst | ₹22.98b |
| Overige uitgaven | ₹16.08b |
| Inkomsten | ₹6.89b |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 153.35 |
| Brutomarge | 40.48% |
| Nettowinstmarge | 12.14% |
| Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde 506285 op de lange termijn?
Bekijk historische prestaties en vergelijkingDividenden
Betaalt 506285 een betrouwbaar dividend?
Zie 506285 dividendgeschiedenis en benchmarks| Bayer CropScience dividenddata | |
|---|---|
| Ex Dividend Datum | Aug 05 2026 |
| Betaaldatum dividend | Sep 18 2026 |
| Dagen tot Ex-dividend | 25 days |
| Dagen tot dividendbetaaldatum | 69 days |
Betaalt 506285 een betrouwbaar dividend?
Zie 506285 dividendgeschiedenis en benchmarksBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/07/10 14:22 |
| Aandelenkoers aan het einde van de dag | 2026/07/10 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2026/03/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Bayer CropScience Limited wordt gevolgd door 24 analisten. 6 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| null null | 360 ONE Capital Market Private Limited |
| Himanshu Binani | Anand Rathi Shares and Stock Brokers Limited |
| null null | Anand Rathi Shares and Stock Brokers Limited |